Ionis Pharmaceuticals, headquartered in Carlsbad, California, develops drugs using antisense technology and has five marketed medicines, including SPINRAZA and QALSODY, with a pipeline focused on neurology and cardiology. The company employs 927 people and has nine medicines in Phase III development.
B Lynne Parshall sold 20,000 shares of IONS on 2 September at $51.49 per share, worth a total of $1.0M. They now own 75,594 IONS shares, or a 23% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
